Heme Oxygenase-1/High Mobility Group Box 1 Pathway May Have a Possible Role in COVID-19 ARDS (Acute Respiratory Distress Syndrome): A Pilot Histological Study.
Cytokine storm
Damage-associated molecular patterns (DAMPs)
Inflammation
Respiratory failure
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
17
12
2022
pubmed:
18
12
2022
medline:
21
12
2022
Statut:
ppublish
Résumé
COVID-19 is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The persistent and excessive inflammatory response can build up a clinical picture that is difficult to manage and potentially fatal. Potent activators of inflammatory phenomena are damage-associated molecular patterns (DAMPs) and, in particular, the high-mobility group box 1 (HMGB1). HMGB1 is an intranuclear protein that is either passively released during hypoxia-related necrosis or actively released by macrophages. Heme oxygenase (HO-1) has an anti-inflammatory effect by inhibiting HMGB1, which could be a therapeutic target to reduce COVID-19 inflammation. In our study, we evaluated CD3, CD4, CD8, HMGB1 and HO-1 in the COVID-19 lung and correlated it to clinical data.
Identifiants
pubmed: 36527623
doi: 10.1007/978-3-031-14190-4_19
doi:
Substances chimiques
Heme Oxygenase-1
EC 1.14.14.18
HMGB1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-116Informations de copyright
© 2022. Springer Nature Switzerland AG.
Références
Adhikari SP, Meng S, Wu YJ et al (2020) Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 9(1):29
doi: 10.1186/s40249-020-00646-x
pubmed: 32183901
pmcid: 7079521
Wölfel R, Corman VM, Guggemos W et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581(7809):465–469
doi: 10.1038/s41586-020-2196-x
pubmed: 32235945
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Gattinoni L, Chiumello D, Caironi P et al (2020) COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 46(6):1099–1102
doi: 10.1007/s00134-020-06033-2
pubmed: 32291463
pmcid: 7154064
Aliberti S, Messinesi G, Gamberini S et al (2014) Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases. BMC Pulm Med 14(1):1–8
doi: 10.1186/1471-2466-14-194
Cicco S, Cicco G, Vacca A et al (2020) Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): two potential targets for COVID-19 treatment. Mediat Inflamm 2020:1–25. https://doi.org/10.1155/2020/7527953
doi: 10.1155/2020/7527953
Tang D, Kang R, Lotze MT et al (2012) PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 249(1):158–175
doi: 10.1111/j.1600-065X.2012.01146.x
pubmed: 22889221
pmcid: 3662247
Liu X, Cao H, Li J et al (2017) Autophagy induced by DAMPs facilitates the inflammation response in lungs undergoing ischemia-reperfusion injury through promoting TRAF6 ubiquitination. Cell Death Differ 24(4):683–693
doi: 10.1038/cdd.2017.1
pubmed: 28157209
pmcid: 5384028
Kang R, Zhang Q, Zeh HJ, Tang D et al (2013) HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19(15):4046–4057
doi: 10.1158/1078-0432.CCR-13-0495
pubmed: 23723299
pmcid: 3732559
Venereau E, De Leo F, Bianchi ME et al (2016) HMGB1 as biomarker and drug target. Pharmacol Res 111:534–544
doi: 10.1016/j.phrs.2016.06.031
pubmed: 27378565
Liu W, Yan ST et al (2015) Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol 63(1):114–121
doi: 10.1016/j.jhep.2015.02.009
pubmed: 25681553
pmcid: 4475488
Zappavigna V, Falciola L, Bianchi ME et al (1996) HMGB1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J 15(18):4981–4991
doi: 10.1002/j.1460-2075.1996.tb00878.x
pubmed: 8890171
pmcid: 452236
Andersson U, Yang H, Harris H (2018) High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol 38:40–48
doi: 10.1016/j.smim.2018.02.011
pubmed: 29530410
Yanai H, Ban T, Wang Z et al (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462(7269):99–103
doi: 10.1038/nature08512
pubmed: 19890330
Kikuchi G, Yoshida T, Noguchi M (2005) Heme oxygenase and heme degradation. Biochem Biophys Res Commun 338(1):558–567
doi: 10.1016/j.bbrc.2005.08.020
pubmed: 16115609
Ryter SW, Alam J, Choi AM (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86(2):583–650. https://doi.org/10.1152/physrev.00011.2005 . PMID 16601269
doi: 10.1152/physrev.00011.2005
pubmed: 16601269
Park EJ, Kim YM, Chang KC (2017) Hemin reduces HMGB1 release by UVB in an AMPK/HO-1-dependent pathway in human keratinocytes HaCaT cells. Arch Med Res 48:423–431
doi: 10.1016/j.arcmed.2017.10.007
pubmed: 29089150
Kalergis González M, Riedel CA, Bueno SM (2017) Pathogenesis during infection respiratory syncytial virus replication and heme oxygenase-1 modulates human. J Immunol 199:212–223. https://doi.org/10.4049/jimmunol.1601414
doi: 10.4049/jimmunol.1601414
pubmed: 28566367
Espinoza JA, González PA, Kalergis AM (2017) Modulation of an-tiviral immunity by heme oxygenase-1. Am J Pathol 187:487–493
doi: 10.1016/j.ajpath.2016.11.011
pubmed: 28082120
Hooper PL (2020) COVID-19 and heme oxygenase: novel insight into the disease and potential therapies. Cell Stress Chaperones 25:707–710
doi: 10.1007/s12192-020-01126-9
pubmed: 32500379
pmcid: 7271958
Singh D, Wasan H, Reet KH (2020) Heme oxygenase-1 modulation: a potential therapeutic target for COVID-19 and associated complications. Free Radic Biol Med 161:263–271
doi: 10.1016/j.freeradbiomed.2020.10.016
pubmed: 33091573
pmcid: 7571447
Wagener FADTG, Pickkers P, Peterson SJ et al (2020) Targeting the heme-heme oxygenase system to prevent severe complications following COVID-19 infections. Antioxidants 9(6):540. https://doi.org/10.3390/antiox9060540
doi: 10.3390/antiox9060540
pubmed: 32575554
pmcid: 7346191
Rossi M, Piagnerelli M, Van Meerhaeghe A et al (2020) Heme oxygenase-1 (HO-1) cytoprotective pathway: a potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome. Med Hypotheses 144:110242. https://doi.org/10.1016/j.mehy.2020.110242 . Epub 3 Sep 2020
doi: 10.1016/j.mehy.2020.110242
pubmed: 33254548
pmcid: 7467863
Elfeky M, Kaede R, Okamatsu-Ogura Y et al Adiponectin inhibits LPS-induced HMGB1 release through an AMP kinase and heme oxygenase-1-dependent pathway in RAW 264 macrophage cells. Mediators Inflamm 2016, Article ID 5701959, 9 pages. https://doi.org/10.1155/2016/5701959
Luo M, Hong XQ, Zhu H et al (2020) The HO-1 signal prevents HMGB1-mediated activation of NLRP3 inflammasomes in lipopolysaccharide-induced acute lung injury in vitro. J Surg Res 247:335–343. https://doi.org/10.1016/j.jss.2019.10.011 . Epub 22 Nov 2019
doi: 10.1016/j.jss.2019.10.011
pubmed: 31767276
Yu Y, Yang Y, Yang M et al (2019) Hydrogen gas reduces HMGB1 release in lung tissues of septic mice in an Nrf2/HO-1-dependent pathway. Int Immunopharmacol 69:11–18. https://doi.org/10.1016/j.intimp.2019.01.022 . Epub 18 Jan 2019
doi: 10.1016/j.intimp.2019.01.022
pubmed: 30660872
Gong Q, Yin H, Fang M et al (2008) Heme oxygenase-1 upregulation significantly inhibits TNF-alpha and Hmgb1 releasing and attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol 8(6):792–798. https://doi.org/10.1016/j.intimp.2008.01.026 . Epub 7 Mar 2008
doi: 10.1016/j.intimp.2008.01.026
pubmed: 18442782
Deng T, Tang C, Zhang G et al (2021) DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities. Cell Death Dis 12:129. https://doi.org/10.1038/s41419-021-03428-x
doi: 10.1038/s41419-021-03428-x
pubmed: 33504767
pmcid: 7838657
Yang A-P, Liu J-P, Tao W-Q et al (2020) The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 84:106504. https://doi.org/10.1016/j.intimp.2020.106504 . Epub 13 Apr 2020
doi: 10.1016/j.intimp.2020.106504
pubmed: 32304994
pmcid: 7152924
Karakike E, Giamarellos-Bourboulis EJ Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. https://doi.org/10.3389/fimmu.2019.00055
Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I (2020) Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. Front Immunol 11:560381. https://doi.org/10.3389/fimmu.2020.560381 . eCollection 2020
doi: 10.3389/fimmu.2020.560381
pubmed: 33072099
pmcid: 7538662